Connect with the future of healthcare
Flomics presents a novel liquid biopsy blood test for the early detection of multiple types of cancer. Our non-invasive test analyzes cell-free RNA expression patterns in blood, identifying cancer biomarkers with Next Generation Sequencing (NGS), powerful bioinformatics, and AI, aiding early-stage diagnosis. Targeting at-risk populations, we have performed pilot studies on the early detection of colon and lung cancer and are expanding to 3 other indications: breast, prostate, pancreas.
Cancer early detection revolution is on the way!
Prototype/preclinical
9.000.000€
2028
Diagnosis
6.3%
500€
Share this project on your website.
Copy and paste the following code into your content.
Flomics Biotech is revolutionizing the early detection of cancer through an innovative liquid biopsy test, unleashing the power of cell-free RNA (cfRNA) molecules that are living snapshots of what is happening in our body in a specific moment. This transformative approach leverages a standard blood draw to screen asymptomatic individuals for complex diseases such as cancer, focusing especially on high-risk groups such as those over 50, smokers, and individuals with a family history of cancer. This proactive screening is vital, as cancer remains the second leading cause of death globally, primarily due to the difficulties in detecting it early when treatment options are most effective.
Problem and Flomics solution:
Current cancer detection methods fall short, as 90% of cancers lack effective early detection tests and are usually only identified when symptomatic and in advanced stages. Flomics addresses this problem with a multi-cancer blood test, merging Next-Generation Sequencing (NGS) and sophisticated bioinformatics that applies AI to identify RNA biomarker signatures in our blood. This will facilitate early and more reliable cancer diagnoses and therefore improve patient outcomes significantly.
Our technology hinges on the dynamic nature of cfRNA molecules produced by cells in response to external stimuli such as complex diseases. These molecules, either free-floating or encapsulated within vesicles, circulate in the blood, providing a real-time snapshot of cellular health. Flomics has developed optimized protocols and sophisticated algorithms, managed by our cloud platform, Stratus®, to survey these molecules efficiently. Our AI-driven approach allows for the detection of abnormal genomic patterns and offers clear clinical interpretations.
We have validated the use of our technology in the detection of cancer with nearly perfect accuracy in pilot studies conducted in collaboration with prestigious medical institutions in Spain and Europe. We are currently expanding these studies and conducting further validations with a larger cohort of over 1300 donors, targeting the early detection of colon, lung, breast, prostate and pancreatic cancer. We also have an ongoing pilot study on the early detection of one type of blood cancer (multiple myeloma).
Market Opportunity and Competition:
The market potential for cancer diagnostics is immense, with the sector valued at $132 billion and growing. Liquid biopsy, a small yet rapidly expanding segment, is projected to reach $14 billion by 2030. Flomics is poised to capture a significant share of this market by offering a solution that not only adds clinical value but also aligns with the latest advances in cancer research and diagnostics.
Competitively, Flomics stands out by focusing on cfRNA instead of traditional DNA-based tests. This not only offers insights into the immediate state of cells but also aids in pinpointing the tissue origin of the cancer, a significant advantage over other methods. Our proprietary platform, Stratus®, enhances our competitive edge, integrating biological insights with cutting-edge bioinformatics to revolutionize cancer diagnostics.
Business Model and Team:
Our business model caters to both direct and indirect sales channels, targeting hospitals and clinics directly or through partnerships with local laboratories. This dual approach ensures wide market penetration and supports scalability and international growth.
The Flomics team is led by a group of seasoned experts in genomics, bioinformatics, and molecular biology, complemented by a stellar advisory board with deep expertise in RNA research and oncology. As we move toward market entry in 2027 with our initial early detection kit for the early detection of colon cancer, our goal is to expand to a multicancer five-cancer screening kit in the following years, post-clinical certification.
«I fully support Flomics and their innovative liquid biopsy technology based on RNA biomarkers. Their innovative approach in early cancer detection, led by a visionary team, promises to revolutionize diagnostics and significantly improve patient outcomes.»
Javier Rivela
Pangaea Oncology
Early cancer detection lacks effective tests, leading to diagnosis at advanced stages. This delay not only increases healthcare costs but also raises the mortality rate by nearly 300%, resulting in an estimated additional expenditure of $85 billion in the healthcare sector.
Current diagnostic methods are often invasive, such as colonoscopies for colorectal cancer, or uncomfortable and based on X-rays, like mammograms for breast cancer. Although effective, these tests are costly and difficult to use as screening tools due to patient discomfort.
Flomics offers an innovative solution for early cancer detection through a liquid biopsy test based on the evaluation of free RNA molecules (cfRNA). This method uses a multi-cancer blood test that combines next-generation sequencing and bioinformatics analysis with artificial intelligence to identify RNA biomarker signatures in the blood, achieving 90% accuracy in early detection of colon cancer in initial trials.
Despite having superior screening parameters, Flomics' success will depend on market access and clinical trials to establish itself in the market and become the new "gold standard" for various types of cancer.
Flomics must demonstrate that its diagnostics not only surpass current standards at the regulatory level but also prove to be more efficient for the healthcare system.
Our experts say
The technique in use is sound, and the team, both internal and advisory, has the potential to pivot and redirect from a technical standpoint. The use of mRNAs as oncobiomarkers, although not 100% in the clinics, has a very promising outlook and obvious biological support.
Rita Vassena
CEO at Fecundis
I believe that liquid biopsy is a powerful tool in personalized medicine and the idea of the team at Flomics to develop a screening solution for multiple cancers is highly innovative.
Marta Marszalek
Clinical Research Manager at Milestone Pharmaceuticals
Early detection of various types of cancer can be extremely beneficial, both in terms of patient survival and health care costs.
Kadri Reis
Researcher | Analyst